Research advance in correlations between fibroblast growth factor-21 and occurrence as well as development of vascular complications of type 2 diabetes mellitus

YANG Song; WANG Chaonan; GU Yuanyuan

doi:10.7619/jcmp.20210947

Journal of Clinical Medicine in Practice > 2021 > 25(15): 128-132. > DOI: 10.7619/jcmp.20210947

YANG Song, WANG Chaonan, GU Yuanyuan. Research advance in correlations between fibroblast growth factor-21 and occurrence as well as development of vascular complications of type 2 diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2021, 25(15): 128-132. DOI: 10.7619/jcmp.20210947

Citation:

PDF (618 KB)

Research advance in correlations between fibroblast growth factor-21 and occurrence as well as development of vascular complications of type 2 diabetes mellitus

1.
Second Department of Endocrinology, Tai'an City Central Hospital of Shandong Province, Taian, Shandong, 271000
2.
Clinical College of Shandong First Medical University, Taian, Shandong, 271000
3.
Department of Pharmacy, Tai'an City Central Hospital of Shandong Province, Taian, Shandong, 271000

More Information

Received Date: March 05, 2021
Available Online: September 27, 2021
Published Date: August 14, 2021

Graphical Abstract

Abstract

Abstract

Type 2 diabetes(T2DM) is a common chronic metabolic disease, and its chronic complications, especially vascular complications, are the main damages of T2DM. Fibroblast growth factor-21(FGF-21) is a newly discovered metabolism regulator, which is considered to be closely linked to the development of T2DM and its complications. We summarized relevant studies about FGF-21 in vascular and macrovascular complications of T2DM. The role of FGF-21 as a biomarker or therapeutic target for vascular complications of T2DM requires further investigations, and its application in predicting vascular complications of T2DM has significant value.
- type 2 diabetes mellitus,
- fibroblast growth factor-21,
- diabetic angiopathy,
- complications

FullText(HTML)

References (46)

References

[1]	LI Y, TENG D, SHI X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study[J]. Bmj, 2020, 369: 997.
[2]	CHEN C, CHEUNG B M, TSO A W, et al. High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5. 4-year population-based prospective study in Chinese subjects[J]. Diabetes Care, 2011, 34(9): 2113-2115. doi: 10.2337/dc11-0294
[3]	BABAKNEJAD N, NAYERI H, HEMMATI R, et al. An Overview of FGF19 and FGF21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity[J]. Horm Metab Res, 2018, 50(6): 441-452. doi: 10.1055/a-0623-2909
[4]	XIAO F, GUO Y, DENG J, et al. Hepatic c-Jun regulates glucose metabolism via FGF21 and modulates body temperature through the neural signals[J]. Mol Metab, 2019, 20: 138-148. doi: 10.1016/j.molmet.2018.12.003
[5]	CHO Y M, KIM D H, LEE K H, et al. The IRE1α-XBP1s pathway promotes insulin-stimulated glucose uptake in adipocytes by increasing PPARγ activity[J]. Exp Mol Med, 2018, 50(8): 1-15. http://www.ncbi.nlm.nih.gov/pubmed/30111834
[6]	周博, 郭秦乐, 李会霞, 等. 成纤维细胞生长因子21通过抑制肥胖小鼠肝脏氧化应激改善胰岛素抵抗[J]. 西安交通大学学报(医学版), 2017, 38(02): 161-165, 187. https://www.cnki.com.cn/Article/CJFDTOTAL-XAYX201702002.htm
[7]	HSU J W, YEH S C, TSAI F Y, et al. Fibroblast growth factor 21 secretion enhances glucose uptake in mono(2-ethylhexyl)phthalate-treated adipocytes[J]. Toxicol In Vitro, 2019, 59: 246-254. doi: 10.1016/j.tiv.2019.04.021
[8]	MAIDA A, ZOTA A, VEGIOPOULOS A, et al. Dietary protein dilution limits dyslipidemia in obesity through FGF21-driven fatty acid clearance[J]. J Nutr Biochem, 2018, 57: 189-196. doi: 10.1016/j.jnutbio.2018.03.027
[9]	LI X, GE H, WEISZMANN J, et al. Inhibition of lipolysis may contribute to the acute regulation of plasma FFA and glucose by FGF21 in ob/ob mice[J]. FEBS Lett, 2009, 583(19): 3230-3234. doi: 10.1016/j.febslet.2009.09.012
[10]	ZHANG F, YU L, LIN X, et al. Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases[J]. Mol Endocrinol, 2015, 29(10): 1400-1413. doi: 10.1210/me.2015-1155
[11]	HUANG Z, XU A, CHEUNG B M Y. The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension[J]. CURR HYPERTENS REP, 2017, 19(4): 28. doi: 10.1007/s11906-017-0730-5
[12]	CUEVAS-RAMOS D, MEHTA R, AGUILAR-SALINAS C A. Fibroblast Growth Factor 21 and Browning of White Adipose Tissue[J]. FRONT PHYSIOL, 2019, 10: 37. doi: 10.3389/fphys.2019.00037
[13]	GENG L, LAM K S L, XU A. the therapeutic Potentlal of FGF21 in metabolic diseases: from bench to clinic[J]. Nat Rev Endocrinol, 2020, 16(11): 654-667. doi: 10.1038/s41574-020-0386-0
[14]	SARAN R, ROBINSON B, ABBOTT K C, et al. US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States[J]. Am J Kidney Dis, 2020, 75(1 Suppl 1): A6-A7. http://www.cghjournal.org/article/S0272-6386(15)00744-1/pdf
[15]	AN S Y, LEE M S, YI S A, et al. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques[J]. Diabetes Research and Clinical Practice, 2012, 96(2): 196-203. doi: 10.1016/j.diabres.2012.01.004
[16]	HINDRICKS J, EBERT T, BACHMANN A, et al. Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction[J]. Clin Endocrinol: Oxf, 2014, 80(6): 918-924. doi: 10.1111/cen.12380
[17]	JIAN W X, PENG W H, JIN J, et al. Association between serum fibroblast growth factor 21 and diabetic nephropathy[J]. Metabolism, 2012, 61(6): 853-859. doi: 10.1016/j.metabol.2011.10.012
[18]	LEE C H, HUI E Y, WOO Y C, et al. Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria[J]. J Clin Endocrinol Metab, 2015, 100(4): 1368-1375. doi: 10.1210/jc.2014-3465
[19]	ZHANG C, SHAO M, YANG H, et al. Attenuation of hyperlipidemia- and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration of fibroblast growth factor-21 is associated with suppression of renal inflammation[J]. PLoS One, 2013, 8(12): e82275. doi: 10.1371/journal.pone.0082275
[20]	KIM H W, LEE J E, CHA J J, et al. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice[J]. Endocrinology, 2013, 154(9): 3366-3376. doi: 10.1210/en.2012-2276
[21]	LIN S, YU L, NI Y, et al. Fibroblast Growth Factor 21 Attenuates Diabetes-Induced Renal Fibrosis by Negatively Regulating TGF-β-p53-Smad2/3-Mediated Epithelial-to-Mesenchymal Transition via Activation of AKT[J]. Diabetes Metab J, 2020, 44(1): 158-172. doi: 10.4093/dmj.2018.0235
[22]	LIN Y, XIAO Y C, ZHU H, et al. Serum fibroblast growth factor 21 levels are correlated with the severity of diabetic retinopathy[J]. J Diabetes Res, 2014, 2014: 929756. http://www.biomedsearch.com/attachments/00/24/89/56/24895642/JDR2014-929756.pdf
[23]	ESTEGHAMATI A, MOMENI A, ABDOLLAHI A, et al. Serum fibroblast growth factor 21 concentrations in type 2 diabetic retinopathy patients[J]. Ann Endocrinol (Paris), 2016, 77(5): 586-592. doi: 10.1016/j.ando.2016.01.005
[24]	ONG K L, JANUSZEWSKI A S, O'CONNELL R, et al. Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study[J]. Diabetologia, 2015, 58(9): 2035-2044. doi: 10.1007/s00125-015-3652-2
[25]	JUNG C H, JUNG S H, KIM B Y, et al. The U-shaped relationship between fibroblast growth factor 21 and microvascular complication in type 2 diabetes mellitus[J]. J Diabetes Complications, 2017, 31(1): 134-140. doi: 10.1016/j.jdiacomp.2016.10.017
[26]	STRUIK D, DOMMERHOLT M B, JONKER J W. Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application[J]. Curr Opin Lipidol, 2019, 30(3): 235-243. doi: 10.1097/MOL.0000000000000599
[27]	FU Z, LOFQVIST C A, SHAO Z, et al. Dietary ω-3 polyunsaturated fatty acids decrease retinal neovascularization by adipose-endoplasmic reticulum stress reduction to increase adiponectin[J]. Am J Clin Nutr, 2015, 101(4): 879-888. doi: 10.3945/ajcn.114.099291
[28]	FU Z, WANG Z, LIU C H, et al. Fibroblast Growth Factor 21 Protects Photoreceptor Function in Type 1 Diabetic Mice[J]. Diabetes, 2018, 67(5): 974-985. doi: 10.2337/db17-0830
[29]	CHOW W S, XU A, WOO Y C, et al. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors[J]. Arterioscler Thromb Vasc Biol, 2013, 33(10): 2454-2459. doi: 10.1161/ATVBAHA.113.301599
[30]	YAFEI S, ELSEWY F, YOUSSEF E, et al. Fibroblast growth factor 21 association with subclinical atherosclerosis and arterial stiffness in type 2 diabetes[J]. Diabetes Metab Syndr, 2019, 13(1): 882-888. doi: 10.1016/j.dsx.2018.12.007
[31]	XIAO Y, LIU L, XU A, et al. Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes[J]. Cardiovasc Diabetol, 2015, 14: 72. doi: 10.1186/s12933-015-0229-9
[32]	LIN Z, PAN X, WU F, et al. Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice[J]. Circulation, 2015, 131(21): 1861-1871. doi: 10.1161/CIRCULATIONAHA.115.015308
[33]	叶青, 董朝晖. 血清成纤维细胞生长因子-21在2型糖尿病合并冠心病中的作用研究[J]. 全科医学临床与教育, 2012, 10(5): 496-499. doi: 10.3969/j.issn.1672-3686.2012.05.005
[34]	伍熙, 赵东晖, 范谦, 等. 成纤维细胞生长因子21对载脂蛋白E基因敲除小鼠动脉粥样硬化病变中内质网应激诱导的凋亡的影响[J]. 中国动脉硬化杂志, 2014, 22(4): 325-329. https://www.cnki.com.cn/Article/CJFDTOTAL-KDYZ201404001.htm
[35]	LENART-LIPIÑSKA M, MATYJASZEK-MATUSZEK B, GERNAND W, et al. Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up[J]. Diabetes Res Clin Pract, 2013, 101(2): 194-200. doi: 10.1016/j.diabres.2013.04.010
[36]	ONG K L, JANUSZEWSKI A S, O'CONNELL R, et al. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study[J]. Diabetologia, 2015, 58(3): 464-473. doi: 10.1007/s00125-014-3458-7
[37]	LEE C H, WOO Y C, CHOW W S, et al. Role of Circulating Fibroblast Growth Factor 21 Measurement in Primary Prevention of Coronary Heart Disease Among Chinese Patients With Type 2 Diabetes Mellitus[J]. J Am Heart Assoc, 2017, 6(6): 115-118.
[38]	JIN L, LIN Z, XU A. Fibroblast Growth Factor 21 Protects against Atherosclerosis via Fine-Tuning the Multiorgan Crosstalk[J]. Diabetes Metab J, 2016, 40(1): 22-31. doi: 10.4093/dmj.2016.40.1.22
[39]	SHI Y, WANG S, PENG H, et al. Fibroblast Growth Factor 21 Attenuates Vascular Calcification by Alleviating Endoplasmic Reticulum Stress Mediated Apoptosis in Rats[J]. Int J Biol Sci, 2019, 15(1): 138-147. doi: 10.7150/ijbs.28873
[40]	ZHU W, WANG C, LIU L, et al. Effects of fibroblast growth factor 21 on cell damage in vitro and atherosclerosis in vivo[J]. Can J Physiol Pharmacol, 2014, 92(11): 927-935. doi: 10.1139/cjpp-2014-0227
[41]	LIU S Q, ROBERTS D, KHARITONENKOV A, et al. Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue[J]. Scientific reports, 2013, 3: 2767. doi: 10.1038/srep02767
[42]	刘雪莲, 谢丽华, 王丽华. 糖尿病合并下肢大血管病变患者血浆FGF-21、SDF-1、Lp(a)水平变化及其临床意义[J]. 临床医学, 2020, 40(4): 63-65. https://www.cnki.com.cn/Article/CJFDTOTAL-EBED202004027.htm
[43]	GIMENO R E, MOLLER D E. FGF21-based pharmacotherapy--potential utility for metabolic disorders[J]. Trends Endocrinol Metab, 2014, 25(6): 303-311. doi: 10.1016/j.tem.2014.03.001
[44]	GAICH G, CHIEN J Y, FU H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes[J]. Cell Metab, 2013, 18(3): 333-340. doi: 10.1016/j.cmet.2013.08.005
[45]	BERGLUND E D, LI C Y, BINA H A, et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity[J]. Endocrinology, 2009, 150(9): 4084-4093. doi: 10.1210/en.2009-0221
[46]	SHI G J, SHI G R, ZHOU J Y, et al. Involvement of growth factors in diabetes mellitus and its complications: A general review[J]. Biomed Pharmacother, 2018, 101: 510-527. doi: 10.1016/j.biopha.2018.02.105

[1]	ZHANG Yu, YAN Hongwei. Effect of ultrasound-guided individualized treatment regimen on outcome of frozen-thawed embryo transfer in patients with adenomyosis[J]. Journal of Clinical Medicine in Practice, 2025, 29(4): 114-118. DOI: 10.7619/jcmp.20243975
[2]	SUN Qingqing, ZHANG Guoqing, YANG Yaru, LI Zhenbei, CAO Yijuan, GU Juan. Eddects of different tubal factors on in vitro fertilization embryo transfer[J]. Journal of Clinical Medicine in Practice, 2021, 25(6): 85-88. DOI: 10.7619/jcmp.20201749
[3]	HE Yuping, HE Xiao, HUANG Jianlei, LIU Dan, LI Ling, HU Zhengli. Effect of body mass index on pregnancy outcomes and perinatal outcomes in polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer[J]. Journal of Clinical Medicine in Practice, 2020, 24(20): 61-63,67. DOI: 10.7619/jcmp.202020017
[4]	CHEN Xiao, MA Rui. Quality nursing intervention in oocyte retrieval of in vitro fertilization and embryo transfer[J]. Journal of Clinical Medicine in Practice, 2020, 24(15): 99-101. DOI: 10.7619/jcmp.202015028
[5]	MA Yan, WANG Min, GAO Ming. Group management process in period of in vitro fertilization and embryo transfer[J]. Journal of Clinical Medicine in Practice, 2020, 24(15): 96-98. DOI: 10.7619/jcmp.202015027
[6]	SHI Jing. Investigation on quality of birth and life of patients with in vitro fertilization-embryo transfer[J]. Journal of Clinical Medicine in Practice, 2020, 24(2): 26-28. DOI: 10.7619/jcmp.202002008
[7]	HOU Xiaoxia, SUN Ting. Effect of endometrial thickness and transplantation time on the incidence of ectopic pregnancy in frozen thawed embryo transplantation[J]. Journal of Clinical Medicine in Practice, 2019, 23(21): 14-17. DOI: 10.7619/jcmp.201921004
[8]	LI Yixue, GUO Jian, NING Yanchun, YU Wanying, GUO Wanru, LIU Heng, FENG Yuhuan. Outcomes of low grade embryos transplanted at cleavage or blastocyst stage[J]. Journal of Clinical Medicine in Practice, 2016, (7): 90-92. DOI: 10.7619/jcmp.201607026
[9]	ZHANG Ping, ZHAO Jing, WANG Yunying, HAN Xiaoyan. Effect of dehidroepiandroszteron on diminished ovarian reserve patients with in vitro fertilization and embryo transfer[J]. Journal of Clinical Medicine in Practice, 2014, (13): 57-59. DOI: 10.7619/jcmp.201413018
[10]	JIA Xiaoli. Application of estrogen constant replacement cycle in frozen-thawed embryo transfer[J]. Journal of Clinical Medicine in Practice, 2013, (13): 148-150. DOI: 10.7619/jcmp.201313054

Cited By

Get Citation

PDF

XML

Article views (361) PDF downloads (23)

Turn off MathJax

Article Contents

Abstract

References

Research advance in correlations between fibroblast growth factor-21 and occurrence as well as development of vascular complications of type 2 diabetes mellitus

Abstract

References

Related Articles

Catalog

Research advance in correlations between fibroblast growth factor-21 and occurrence as well as development of vascular complications of type 2 diabetes mellitus

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content